Amersham plc appoints Peter Loescher as Chief Operating Officer

17-Nov-2003
Amersham plc announced the appointment of Peter Loescher to the role of Chief Operating Officer, effective 1 January 2004. Mr Loescher, 46, joined the company in December 2002 as President of Amersham Health and an Executive member of the Amersham plc Board. In this new role Mr Loescher will continue to lead Amersham Health and to report to Sir William Castell, Chief Executive, Amersham. Andrew Carr, President Discovery Systems and Peter Ehrenheim, President Protein Separations will report to Mr Loescher with respect to their operational responsibilities. Sir William Castell, Chief Executive of Amersham, said: "Since joining Amersham Peter has brought a more customer-led approach to our marketing operations and has realigned Amersham Health's focus on its core medical diagnostics business. His appointment as Chief Operating Officer reflects our confidence in his ability to take on wider operational responsibility for the delivery of our business goals." Prior to joining Amersham, Mr Loescher, was Chairman and Chief Executive Officer of Aventis Pharma in Japan, the world's second largest pharmaceutical market. Mr Loescher is a graduate of the Vienna University of Economics and Business Administration, and has also studied at the Chinese University of Hong Kong and Harvard Business School.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures